Tencent

"Versius is very well suited to our needs as a world-leading thoracic surgery department. We have successfully helped patients get the benefit of robotic assisted surgery and we look forward to developing our robotics programme working with CMR and other centres around the world as the adoption of Versius continues."

"Our vision is a future where cell and gene therapies are safer, more efficient, and affordable for patients. Operating at the intersection of biology, bioinformatics and data science, our INDUCE-seq platform offers an unbiased, end-to-end solution that expedites the measurement and assessment of off-target gene editing during therapeutic development. This provides essential information required to progress therapeutic programs that leverage gene editing and mitigate potential risks that can result in later-stage clinical failures. By developing a deployable PaaS offering, we have the opportunity to provide the cell and gene therapy community with this much-needed solution and achieve rapid market growth."

"The world is seeing a tectonic shift in the way businesses work and hire: from local-first to global- and remote-first,"

"This major fundraise is a substantial validation of both our team and our world-leading technology. We are fortunate to have the support from new and current investors who have recognised the importance of the microbiome's therapeutic potential and Microbiotica's unique capabilities."

"Over the past decade Brainomix has created the market for stroke AI imaging. As a spin-out from the University of Oxford it is an example of the UK's world-leading strengths in life sciences and AI-enabled medtech, combining expertise in clinical care and software development with more than 150 years' experience in the field across its leadership team."

"The metaverse concept is not new to Ultraleap. It has always been our mission to remove boundaries between physical and digital worlds. The pandemic has accelerated the rise of the term as more people now understand the power of enhancing the physical world with digital elements."

"This latest financing equips CMR with significant funds to accelerate our mission of bringing Versius to hospitals worldwide, whilst providing full flexibility to achieve our goals. This major injection of capital that now values us at $3billion not only reflects the level of interest we have seen in our product, but also the scale of the business, and will enable significant technology developments and global expansion. As the lead investor, SoftBank has a wealth of experience supporting disruptive business models and innovative technologies, and we look forward to leveraging their expertise and extensive ecosystem. I would also like to thank our existing investors for their long-term support."

"We are excited about the opportunity to work with Oxbotica to develop a wide range of autonomous solutions that truly have the potential to transform both our and our partners’ CFC and service delivery operations, while also giving all end customers the widest range of options and flexibility."

"We are thrilled to be supporting Congenica in developing their world-leading technology to deliver life-changing answers. At QVentures, we strive to support cutting-edge technology companies that really change how an industry operates and we believe David and his team are doing just that. We are pleased that QVentures’ Family Offices and UHNWI investors could join us on that journey."

"We are very excited about the amazing endorsement we have received from new and existing investors. This round of investment marks a key chapter in Oxbotica’s continued growth and pushes us forward in commercialising our autonomous software today, through key strategic go-to-market partnerships. The high-quality and global footprint of our investors cements our position as a leader in autonomy. We will use funds raised to accelerate the global deployment of our transformative technology."

"firstminute exists to support entrepreneurs, at the earliest stage, in creating platforms that will re-shape our world. Globally, outstanding technical minds are plotting how to solve the toughest societal and economic challenges with software. Many of these challenges have been exacerbated by the pandemic and its recession. Our healthcare systems, workplaces and educational establishments face fresh complexities. The service economy is having to re-imagine itself. The gap between financial markets and the real economy is growing wider (with the young most at risk). Start-ups are not a panacea, but emerging technology companies have a key role to play in today’s recovery strategy, both in their mindset and the products they will create. firstminute aims to be a talent magnet to star founders building the most ambitious businesses, wherever we find them."

"Genomic medicine is revolutionising healthcare, transforming outcomes for patients by providing clinicians with fast, accurate and early diagnoses and the information needed to provide life-changing answers for their patients, improving wellbeing and disease management. This new funding will allow us to build on our established foundation in rare disease and bring the power of our platform to new indications and new markets. We welcome our new investors to Congenica and are grateful to our existing investors for their continued support."

"Using AI-powered digital twin technology to replicate the real world in a digital capacity is the next step towards using data to make better decisions, not only in Infrastructure but in how we impact the world as people. SenSat has scaled rapidly in the past year, and we have big plans for this first major round of investment, adding to our world-class AI expertise, and enabling fresh partnerships with innovators in a range of different fields. With Tencent, we share similar ambitions about the impact of enterprise internet on laggard industries and how that can lead to us operating our world more sustainably."

"Today’s announcement amplifies our commitment to global markets, whilst fuelling our industry momentum as we continue to build Everledger. Having this strong investor cohort join us at this stage in our development is both validation of the innovation we’ve displayed to date, and a statement of future intent. They will support us in bringing more visibility to good business practices in industries that impact millions, if not billions of people in developing countries."

"This investment is a huge sign of confidence in our efforts to be at the forefront of how enterprises use machines"